253 related articles for article (PubMed ID: 8866775)
1. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables.
Naber D
Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():133-8. PubMed ID: 8866775
[TBL] [Abstract][Full Text] [Related]
2. Correlation of subjective well-being in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status.
Putzhammer A; Perfahl M; Pfeiff L; Hajak G
Pharmacopsychiatry; 2005 May; 38(3):132-8. PubMed ID: 15902585
[TBL] [Abstract][Full Text] [Related]
3. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale.
de Haan L; Weisfelt M; Dingemans PM; Linszen DH; Wouters L
Psychopharmacology (Berl); 2002 Jun; 162(1):24-8. PubMed ID: 12107613
[TBL] [Abstract][Full Text] [Related]
4. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
[TBL] [Abstract][Full Text] [Related]
5. Subjective well-being and quality of life under atypical antipsychotic treatment.
Karow A; Naber D
Psychopharmacology (Berl); 2002 Jun; 162(1):3-10. PubMed ID: 12107610
[TBL] [Abstract][Full Text] [Related]
6. Performance of the Italian version of the subjective well-being under neuroleptic (SWN) scale in schizophrenic outpatients.
Balestrieri M; Giaroli G; Mazzi M; Bellantuono C
Pharmacopsychiatry; 2006 May; 39(3):81-4. PubMed ID: 16721695
[TBL] [Abstract][Full Text] [Related]
7. Subjective assessments of the quality of life, well-being and self-efficacy in patients with schizophrenia.
Chino B; Nemoto T; Fujii C; Mizuno M
Psychiatry Clin Neurosci; 2009 Aug; 63(4):521-8. PubMed ID: 19531107
[TBL] [Abstract][Full Text] [Related]
8. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride.
Linden M; Scheel T; Eich FX
J Psychopharmacol; 2006 Nov; 20(6):815-23. PubMed ID: 16401647
[TBL] [Abstract][Full Text] [Related]
9. Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance.
Lambert M; Schimmelmann BG; Karow A; Naber D
Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S181-90. PubMed ID: 14677077
[TBL] [Abstract][Full Text] [Related]
10. Association of adverse drug effects with subjective well-being in patients with schizophrenia receiving stable doses of risperidone.
Kim JH; Kim MJ
Clin Neuropharmacol; 2009; 32(5):250-3. PubMed ID: 19620847
[TBL] [Abstract][Full Text] [Related]
11. [Quality of life in schizophrenic patients treated with classic and "old" atypical neuroleptics].
Jarema M; Konieczyńska Z
Psychiatr Pol; 2000; 34(2):275-88. PubMed ID: 10974941
[TBL] [Abstract][Full Text] [Related]
12. The relationship between depressive symptoms and subjective well-being in newly admitted patients with schizophrenia.
Kim JH; Ann JH; Kim MJ
Compr Psychiatry; 2010; 51(2):165-70. PubMed ID: 20152297
[TBL] [Abstract][Full Text] [Related]
13. Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?
Schennach-Wolff R; Jäger M; Obermeier M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Klingberg S; Gastpar M; Seemüller F; Möller HJ; Riedel M
World J Biol Psychiatry; 2010 Aug; 11(5):729-38. PubMed ID: 20380620
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia.
Meltzer HY; Bobo WV; Lee MA; Cola P; Jayathilake K
Psychiatry Res; 2010 May; 177(3):286-93. PubMed ID: 20378185
[TBL] [Abstract][Full Text] [Related]
15. [Subjective view of positive symptoms and quality of life in patients with schizophrenia].
Karow A; Schäfer I; Hirdes F; Osterwald C; Naber D
Psychiatr Prax; 2008 Sep; 35(6):286-93. PubMed ID: 18504688
[TBL] [Abstract][Full Text] [Related]
16. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects.
Hofer A; Kemmler G; Eder U; Edlinger M; Hummer M; Fleischhacker WW
J Clin Psychiatry; 2004 Jul; 65(7):932-9. PubMed ID: 15291682
[TBL] [Abstract][Full Text] [Related]
17. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.
Löffler W; Kilian R; Toumi M; Angermeyer MC
Pharmacopsychiatry; 2003 May; 36(3):105-12. PubMed ID: 12806568
[TBL] [Abstract][Full Text] [Related]
18. [Relationships between insight and medication adherence in subjects with psychosis].
Droulout T; Liraud F; Verdoux H
Encephale; 2003; 29(5):430-7. PubMed ID: 14615692
[TBL] [Abstract][Full Text] [Related]
19. How to distinguish between the neuroleptic-induced deficit syndrome, depression and disease-related negative symptoms in schizophrenia.
Barnes TR; McPhillips MA
Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():115-21. PubMed ID: 8866773
[TBL] [Abstract][Full Text] [Related]
20. [Alexithymia in negative symptom and non-negative symptom schizophrenia].
Nkam I; Langlois-Thery S; Dollfus S; Petit M
Encephale; 1997; 23(5):358-63. PubMed ID: 9453928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
